慢性丙型肝炎基因3型感染抗病毒治疗的真实世界使用、有效性和安全性
德国丙型肝炎登记研究纳入1322例基因3型患者,2014年2月至2015年9月间使用五种治疗方案,治疗方案的选择随新批准和指南推荐快速变化,符合方案人群持续病毒学应答率从PegIFN+RBV组的80.9%至PegIFN+RBV+SOF组的96.1%,含利巴韦林方案不良事件更多且血红蛋白下降更明显。
要点
- 符合方案持续病毒学应答率从PegIFN+RBV组的80.9%至PegIFN+RBV+SOF组的96.1%。
- 经治肝硬化患者中SOF+RBV的持续病毒学应答率为68%,DCV+SOF±RBV为90%-95%。
- 含利巴韦林方案不良事件更多且血红蛋白下降更明显。
核心结论
- 真实世界数据可验证此前基于有限数据获批的治疗方案的有效性和安全性,尤其对特定亚组患者。
- 本研究展示了新科学数据、新治疗指南、新药批准和标签变更如何快速进入常规临床实践。
研究设计与样本
- 德国丙型肝炎登记研究是一项大型全国性非干预性真实世界研究。
- 共纳入1322例基因3型患者,其中211例未治疗、1111例已治疗。
主要发现
- 2014年2月至2015年9月间使用了五种治疗方案:PegIFN+RBV、PegIFN+RBV+SOF、SOF+RBV、DCV+SOF±RBV、LDV/SOF±RBV。
- 研究期间治疗 uptake 和治疗方案使用变化显著且迅速,受新批准、指南推荐和标签更新影响。
- 以PegIFN为基础的治疗持续减少,以DCV为基础的治疗增加,但在LDV/SOF获批后出现一次中断,LDV/SOF常被使用直至新指南推荐基因3型不使用该联合方案。
- 符合方案持续病毒学应答率从PegIFN+RBV组的80.9%至PegIFN+RBV+SOF组的96.1%。
- 经治肝硬化患者中SOF+RBV的持续病毒学应答率为68%,DCV+SOF±RBV为90%-95%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of chronic hepatitis C genotype 3 (GT3) is more challenging compared with other genotypes. Since 2014, several new treatment regimens have been approved but sometimes based on limited data. AIM: To validate the use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection under real-word conditions. METHODS: The German Hepatitis C-Registry is a large national non-interventional real-world study for patients with chronic hepatitis C. A total of 1322 GT3 patients were enrolled (211 untreated and 1111 treated patients). RESULTS: Between February 2014 and September 2015, five different treatment strategies have been used (PegIFN+RBV, PegIFN+RBV+SOF, SOF+RBV, DCV+SOF±RBV, LDV/SOF±RBV). Treatment uptake and use of treatment concepts changed markedly and rapidly during the study influenced by new approvals, guideline recommendations, and label updates. PegIFN-based therapies constantly declined while DCV-based therapies increased with one interruption after the approval of LDV/SOF, which was frequently used until new guidelines recommended not using this combination for GT3. Per-protocol SVR ranged from 80.9% in the PegIFN+RBV group to 96.1% in PegIFN+RBV+SOF treated patients. Treatment-experienced patients with cirrhosis showed a suboptimal SVR of 68% for SOF+RBV but a high SVR of 90-95% for DCV+SOF±RBV. The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV containing regimens. CONCLUSIONS: Real-world data can validate the effectiveness and safety for treatment regimens that had previously been approved with limited data, in particular for specific subgroups of patients. The present study demonstrates how rapid new scientific data, new treatment guidelines, new drug approvals and label changes are implemented into routine clinical practice today.
引用
- Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017. PMID: 28078723. doi:10.1111/apt.13925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。